A study published, in The Lancet, found that prostate-specific membrane antigen (PSMA) PET/CT is a suitable replacement for conventional imaging in patients with prostate cancer that provides superior accuracy to the combined findings of CT and bone scanning.1
Though the study did not assess whether the scans had any effect on patient survival, the researchers suggest that this approach could improve outcomes by helping doctors decide whether to offer a localized treatment, such as surgery or radiotherapy, or to use more advanced treatments to treat the whole body if the cancer has already spread.
“Taken together, our findings indicate that PSMA PET/CT scans offer greater accuracy than conventional imaging and can better inform treatment decisions,” study lead Michael Hofman, of the Peter MacCallum Cancer Center in Australia, said in a press release.2 “We recommend that…